


OCT 26 2007

AMENDMENTS TO THE CLAIMS

The following Listing of Claims shall replace any prior listing of claims. No new matter has been added.


Listing of Claims

1. (Original) A compound as shown in formula (A):



wherein,

R is methyl, ethyl, propyl, *iso*-propyl, or butyl;




R' is methyl, ethyl, propyl, *iso*-propyl, or butyl;

R'' is methyl, ethyl, propyl, *iso*-propyl, or butyl; and


M is a metal ion.

2. (Original) The compound of Claim 1 having the following formula:



wherein R is as defined above.


3. (Original) The compound of Claim 1 having the following formula:



wherein R is as defined above; and

M is lithium, sodium, potassium or calcium.

4. (Original) The compound of Claim 1 having the following formula:



wherein, R, R', and R'' are as defined above; and

M is lithium, sodium, potassium or calcium.

5. (Original) The compound of Claim 1, wherein the compound is selected from the group consisting of:

Compound 1: 2,2-dimethylbutyric acid-3-hydroxy-8-[2-(4-hydroxy-6-oxo-tetrahydro pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl ester;

Compound 2: the compound of formula (II), wherein R=methyl, M=K;

Compound 3: the compound of formula (III), wherein R=R'=R''=methyl, M=K.

6. (Original) A pharmaceutical composition comprising an effective amount of the compound of formula (A) and a pharmaceutically acceptable carrier.

7. (Currently Amended) The synthetic method of the compound of formula (I), wherein the method comprises the steps of:

starting from pravastatin, after the protection of the carboxylic group with formation of alkali metal salt, the 2-position of the 2-methylbutyryl group in the 8-position of the hydrogenated naphthalene is alkylated with alkyl halide; or the method comprises the following steps:

starting from pravastatin, after the carboxylic group is converted into amide and the hydroxyl group is protected by siloxane, the 2-methylbutyryl group in the 8-position of the hydrogenated naphthalene is transformed into 2,2-dimethylbutyryl group with alkyl halide.

8. (Original) The synthetic method of the compound of formula (II), comprising the steps of:

reacting β -hydroxyl carboxylic acid, i.e., the product of the ring-opening reaction of the compound of formula (I), with a base of formula MOH, thereby forming the compound of formula (II), wherein M is lithium, sodium or potassium.

9. (Original) The synthetic method of the compound of formula (III), comprising the steps of:

in the presence of ketone or 2,2-dialkoxylpropane, converting the β , δ -dihydroxyl carboxylic acid, i.e., the product of the ring-opening reaction of the compound of formula (I), into 6-member ring ketal by acid catalysis, and

reacting the ketal with the base of formula MOH, thereby forming the compound of formula (III),

wherein M is lithium, sodium or potassium.

10. (Currently Amended) A method of manufacturing a medicament for inhibiting hydroxymethyl glutaryl coenzyme A reductase, comprising:

preparing use of the compound of formula (A) as in claim 1 in the manufacture of drugs for inhibiting hydroxymethyl glutaryl coenzyme A reductase; and preparing a pharmaceutical composition including the compound of formula A.